Skip Navigation LinksHome»Media Center»Corporate News

Corporate News

International Biotech Expert Dr. Lutz Hilbrich,
Now the CEO of ProBioGen AG

Minapharm pharmaceuticals, the leading biopharmaceutical company in Egypt, Africa and the Middle East, announced on June the 1st, the appointment of Dr. Lutz Hilbrich, an experienced biotech executive, as the new CEO of its Berlin-based subsidiary ProBioGen AG.

Minapharm's 2018 Summer Internship: A Great Success

Minapharm's summer internship for 2018 has concluded successfully after two great months of learning. The internship was offered from July till to early September ...

Minapharm Awarded as One of the Top Companies in Egypt

Minapharm was honored for its role as one of the 100 top companies operating in Egypt and one of the only two top pharmaceutical companies in 2017...

Our Subsidiary ProBioGen celebrates the 20th anniversary: €20 million investment in Mammalian Manufacturing Expansion

On the occasion of its 20th anniversary,ProBioGen AG announced to invest 20€ million and to double its workforce ...

VTU Technology, Austria and MINAPHARM Pharmaceuticals S.A.E., Egypt enter into development and license agreement

VTU Technology and MINAPHARM Pharmaceuticals announced today, that they have entered into a licensing agreement to develop a therapeutic, recombinant Human Serum Albumin (rHSA). Under the terms of the agreement, VTU Technology grants MINAPHARM access to VTU´s Pichia pastoris protein expression technology for rHSA production.

MINAPHARM Pharmaceuticals acquires majority stake in ProBioGen – Dr. Wieland Wolf appointed new CEO

ProBioGen AG announced today that MINAPHARM Pharmaceuticals, Cairo, has completed the acquisition of 95 % of the share capital of ProBioGen, an internationally renowned German cell line development and contract manufacturing specialist. The total purchase price of EUR 30.4 million includes earn-out payments which are conditional upon the achievement of defined milestones. ProBioGen will continue to be a committed technology and service provider for its global biopharmaceutical clients. The company will also continue to develop proprietary technologies in the field of biopharmaceutical products.

Cyplasin Biomedical and Minapharm SAE announce Term Sheet Agreement for Distribution and Manufacture of Cyplasin Products

Cyplasin Biomedical (CPBM: OTCBB and XYI1:FRA) and Minapharnn SAE (Cairo and Alexandria Stock Exchange: MIPH) jointly announced the successful negotiation and signing of a binding term sheet agreement for the sales/marketing and distribution of Cyplasin's product C-Virin for use with chronically infected Hepatitis C patients within the Middle East and MENA regions. The agreement also encompasses the eventual manufacture and marketing of Cyplasin's future vaccine product C- Vaxin once it is available. The agreement further includes a small convertible debt loan from Minapharm to Cyplasin which will be used for initial manufacturing setups.

1 2 3 4 

Scientific News Read More »

Latest Products Read More »


Betolvex PFS

A MODERN AGE for vitamin B12

Newsletter Sign-up

Stay connected, subscribe to our newsletter for news and updates.


Office Address

Address: El-Bardissi St., 2T Takseem Asmaa Fahmy St., Heliopolis, Cairo - Egypt.
Phone: (+202) 2414-3170/1/2/3/4/5
Fax: (+202) 2414-3179

Social Media